Compare Agilent Technologies Inc (A) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Intuitive Surgical, Inc. — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Intuitive Surgical, Inc. trades at $400 (market cap $138.97B). The key difference: Intuitive Surgical, Inc. is far larger — about 3.3× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays a 0.69% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| A | ISRG | |
|---|---|---|
Market Cap | $42.00B | $138.97B |
Sector | Health | Health |
52-Week High | $157.20 | $592.85 |
52-Week Low | $110.24 | $332.02 |
Enterprise Value | $43.55B | $133.76B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Intuitive Surgical (ISRG) trades at $378.81, up 1.36% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bullish technical signals despite premium valuations (P/E 43.44, P/S 12.35), supported by robust revenue growth reaching $10.06B in 2025 and expanding profit margins of 28.45%. Recent news highlights da Vinci 5 adoption driving procedure growth beyond urology.
Outlook remains positive with 68% analyst buy ratings and $519.05 price target suggesting 37% upside. Key risks include competitive pressure from Medtronic/J&J robots and potential U.S. procedure softness. The combination of durable demand and innovation pipeline supports long-term growth potential for MedTech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
